392 related articles for article (PubMed ID: 33801599)
21. c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation.
Vaqué JP; Fernández-García B; García-Sanz P; Ferrandiz N; Bretones G; Calvo F; Crespo P; Marín MC; León J
Mol Cancer Res; 2008 Feb; 6(2):325-39. PubMed ID: 18314492
[TBL] [Abstract][Full Text] [Related]
22. Myc antagonizes Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway.
Vaqué JP; Navascues J; Shiio Y; Laiho M; Ajenjo N; Mauleon I; Matallanas D; Crespo P; León J
J Biol Chem; 2005 Jan; 280(2):1112-22. PubMed ID: 15528212
[TBL] [Abstract][Full Text] [Related]
23. MYC's Fine Line Between B Cell Development and Malignancy.
de Barrios O; Meler A; Parra M
Cells; 2020 Feb; 9(2):. PubMed ID: 32102485
[TBL] [Abstract][Full Text] [Related]
24. Insights into the Links between MYC and 3D Chromatin Structure and Epigenetics Regulation: Implications for Cancer Therapy.
Amjadi-Moheb F; Paniri A; Akhavan-Niaki H
Cancer Res; 2021 Apr; 81(8):1925-1936. PubMed ID: 33472888
[No Abstract] [Full Text] [Related]
25. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
26. Translocations involving c-myc and c-myc function.
Boxer LM; Dang CV
Oncogene; 2001 Sep; 20(40):5595-610. PubMed ID: 11607812
[TBL] [Abstract][Full Text] [Related]
27. NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number.
Woo CW; Lucarelli E; Thiele CJ
Oncogene; 2004 Feb; 23(8):1522-30. PubMed ID: 14691455
[TBL] [Abstract][Full Text] [Related]
28. Bptf determines oncogenic addiction in aggressive B-cell lymphomas.
Richart L; Felipe I; Delgado P; Andrés MP; Prieto J; Pozo ND; García JF; Piris MA; Ramiro A; Real FX
Oncogene; 2020 Jun; 39(25):4884-4895. PubMed ID: 32451433
[TBL] [Abstract][Full Text] [Related]
29. BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis.
Richart L; Carrillo-de Santa Pau E; Río-Machín A; de Andrés MP; Cigudosa JC; Lobo VJS; Real FX
Nat Commun; 2016 Jan; 7():10153. PubMed ID: 26729287
[TBL] [Abstract][Full Text] [Related]
30. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
[No Abstract] [Full Text] [Related]
31. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
32. c-myc and skp2 coordinate p27 degradation, vascular smooth muscle proliferation, and neointima formation induced by the parathyroid hormone-related protein.
Sicari BM; Troxell R; Salim F; Tanwir M; Takane KK; Fiaschi-Taesch N
Endocrinology; 2012 Feb; 153(2):861-72. PubMed ID: 22210745
[TBL] [Abstract][Full Text] [Related]
33. Regulation of cancer cell metabolism: oncogenic MYC in the driver's seat.
Dong Y; Tu R; Liu H; Qing G
Signal Transduct Target Ther; 2020 Jul; 5(1):124. PubMed ID: 32651356
[TBL] [Abstract][Full Text] [Related]
34. Korean red ginseng extract induces proliferation to differentiation transition of human acute promyelocytic leukemia cells via MYC-SKP2-CDKN1B axis.
Jo S; Lee H; Kim S; Lee CH; Chung H
J Ethnopharmacol; 2013 Nov; 150(2):700-7. PubMed ID: 24095829
[TBL] [Abstract][Full Text] [Related]
35. The brain acid-soluble protein 1 (BASP1) interferes with the oncogenic capacity of MYC and its binding to calmodulin.
Hartl M; Puglisi K; Nist A; Raffeiner P; Bister K
Mol Oncol; 2020 Mar; 14(3):625-644. PubMed ID: 31944520
[TBL] [Abstract][Full Text] [Related]
36. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells.
Itkonen HM; Urbanucci A; Martin SE; Khan A; Mathelier A; Thiede B; Walker S; Mills IG
Theranostics; 2019; 9(8):2183-2197. PubMed ID: 31149037
[TBL] [Abstract][Full Text] [Related]
37. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
Marcotte R; Chen JM; Huard S; Wang E
J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
[TBL] [Abstract][Full Text] [Related]
38. Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Shao P; Liu Q; Maina PK; Cui J; Bair TB; Li T; Umesalma S; Zhang W; Qi HH
Nucleic Acids Res; 2017 Feb; 45(4):1687-1702. PubMed ID: 27899639
[TBL] [Abstract][Full Text] [Related]
39. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
[TBL] [Abstract][Full Text] [Related]
40. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.
Yoon JW; Gallant M; Lamm ML; Iannaccone S; Vieux KF; Proytcheva M; Hyjek E; Iannaccone P; Walterhouse D
Mol Cancer Res; 2013 Jun; 11(6):604-15. PubMed ID: 23525267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
